Matthieu Duchmann, Jean‐Baptiste Micol, Nicolas Duployez, Emmanuel Raffoux, Xavier Thomas, Jean‐Pierre Marolleau, Thorsten Braun, Lionel Adès, Sylvain Chantepie, Émilie Lemasle, Céline Berthon, Jean‐Valère Malfuson, Cécile Pautas, Juliette Lambert, Nicolas Boissel, Karine Celli‐Lebras, Denis Caillot, Pascal Turlure, Norbert Vey, Arnaud Pigneux, Christian Récher, Christine Terré, Claude Gardin, Raphaël Itzykson, Claude Preudhomme, Hervé Dombret, Stéphane de Botton,
In patients with isocitrate dehydrogenase (IDH)-mutated acute myeloid leukemia (AML) treated by intensive chemotherapy (IC), prognostic significance of co-occurring genetic alterations and allogeneic hematopoietic stem cell transplantation (HSCT) are of particular interest with the advent of IDH1/2 mutant inhibitors. We retrospectively analyzed 319 patients with newly diagnosed AML (127 with IDH1, 135 with IDH2R140, and 57 with IDH2R172 mutations) treated with IC in 3 Acute Leukemia French Association ...
Tópico(s): Acute Lymphoblastic Leukemia research
2021 - Elsevier BV | Blood
Raphaël Itzykson, Claude Gardin, Cécile Pautas, Xavier Thomas, Pascal Turlure, Emmanuel Raffoux, Christine Terré, Pierre Fenaux, Sylvie Castaigné, Hervé Dombret, Nicolas Boissel,
Background There is no standard post-remission therapy in older patients with acute myeloid leukemia.Design and Methods From 1999 to 2006, the Acute Leukemia French Association group ran two concurrent randomized trials with overlapping inclusion criteria for patients aged 65 to 70 with acute myeloid leukemia, with different post-remission strategies: two intensive courses in the 9801 trial, one intensive course or six outpatient courses in the 9803 trial. We analyzed the outcome of these patients ...
Tópico(s): Acute Lymphoblastic Leukemia research
2011 - Ferrata Storti Foundation | Haematologica
Particle seas were introduced by Claude Itzykson to give a direct combinatorial proof of the Jacobi triple product [Viennot, Empilements, 1999]. We show here how generalized particle seas ...
Tópico(s): Mathematical functions and polynomials
2003 - Elsevier BV | Advances in Applied Mathematics
... Aug.31-Sept.5, 1996, in memory of Claude Itzykson)
Tópico(s): Particle physics theoretical and experimental studies
1997 - Elsevier BV | Nuclear Physics B - Proceedings Supplements
Laurent Baulieu, Vladimir Kazakov, Marco Picco, Paul Windey,
... The School was dedicated to the memory of Claude Itzykson. This session focused on the recent pr
Tópico(s): Quantum Mechanics and Applications
1997 - Springer Nature | NATO ASI series. Series B : Physics
... and Computer Modelling, Vol. 26, No. 8-10Dedication Claude Itzykson (1938–1995)M. Bousquet-Mélou, D.E. Loeb ...
Tópico(s): Homotopy and Cohomology in Algebraic Topology
1994 - World Scientific | International Journal of Modern Physics B
Nicolas Duployez, Loïc Vasseur, Rathana Kim, Laëtitia Largeaud, Marie Passet, Anaïs L’Haridon, Pierre Lemaire, Laurène Fenwarth, Sandrine Geffroy, Nathalie Hélevaut, Karine Celli‐Lebras, Lionel Adès, Delphine Lebon, Céline Berthon, Alice Marceau‐Renaut, Meyling Cheok, Juliette Lambert, Christian Récher, Emmanuel Raffoux, Jean‐Baptiste Micol, Arnaud Pigneux, Claude Gardin, Éric Delabesse, Jean Soulier, Mathilde Hunault, Hervé Dombret, Raphaël Itzykson, Emmanuelle Clappier, Claude Preudhomme,
Abstract Tandem duplications (TDs) of the UBTF gene have been recently described as a recurrent alteration in pediatric acute myeloid leukemia (AML). Here, by screening 1946 newly diagnosed adult AML, we found that UBTF -TDs occur in about 3% of patients aged 18–60 years, in a mutually exclusive pattern with other known AML subtype-defining alterations. The characteristics of 59 adults with UBTF -TD AML included young age (median 37 years), low bone marrow (BM) blast infiltration (median 25%), and high ...
Tópico(s): Cancer Genomics and Diagnostics
2023 - Springer Nature | Leukemia
Nicolas Duployez, Laëtitia Largeaud, Matthieu Duchmann, Rathana Kim, Julie Rieunier, Juliette Lambert, Audrey Bidet, Lise Larcher, Jean Lemoine, François Delhommeau, Pierre Hirsch, Laurène Fenwarth, Olivier Kosmider, Justine Decroocq, Anne Bouvier, Yannick Le Bris, Marlène Ochmann, Alberto Santagostino, Lionel Adès, Pierre Fenaux, Xavier Thomas, Jean‐Baptiste Micol, Claude Gardin, Raphaël Itzykson, Jean Soulier, Emmanuelle Clappier, Christian Récher, Claude Preudhomme, Arnaud Pigneux, Hervé Dombret, Éric Delabesse, Marie Sébert,
Abstract DDX41 germline mutations (DDX41MutGL) are the most common genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia (AML). Recent reports suggest that DDX41MutGL myeloid malignancies could be considered as a distinct entity, even if their specific presentation and outcome remain to be defined. We describe here the clinical and biological features of 191 patients with DDX41MutGL AML. Baseline characteristics and outcome of 86 of these patients, treated with intensive chemotherapy ...
Tópico(s): Histone Deacetylase Inhibitors Research
2022 - Elsevier BV | Blood
Matthieu Duchmann, Jean-Baptiste Micol, Nicolas Duployez, Emmanuel Raffoux, Xavier Thomas, Jean-Pierre Marolleau, Thorsten Braun, Lionel Adès, Sylvain Chantepie, Émilie Lemasle, Céline Berthon, Jean Valère Malfuson, Cécile Pautas, Juliette Lambert, Nicolas Boissel, Karine Celli‐Lebras, Denis Caillot, Pascal Turlure, Norbert Vey, Arnaud Pigneux, Christian Récher, Christine Terré, Claude Gardin, Raphaël Itzykson, Claude Preudhomme, Hervé Dombret, Stéphane de Botton,
Background : Point mutations in isocitrate dehydrogenase (IDH) genes are seen in 20% of adult patients (pts) with acute myeloid leukemia (AML). Prognostic significance of each IDH1/2 mutation (mut) analyzed with co-occurring mutations treated with intensive chemotherapy (IC) remains inconsistent, particularly with the advent of IDH inhibitors. Furthermore, the role of allogeneic stem cell transplantation (SCT) in IDH-mutated without favorable-risk features is not known. Patients & Methods: Between 2009 and ...
Tópico(s): Cancer Genomics and Diagnostics
2019 - Elsevier BV | Blood
Raphaël Itzykson, Claude Gardin, Pierre Fenaux,
Myelodysplastic syndromes (MDS) remain challenging to both clinicians and biologists. This year's edition of the Annual Meeting of the American Society of Hematology has provided several breakthroughs in the biology and therapeutics of MDS, such as uncovering of the molecular genetics of the 5q- syndrome and clear evidence of a survival advantage with a hypomethylating agent in high-risk MDS. We summarize those advances and delineate some perspectives for these diseases.
Tópico(s): Lymphoma Diagnosis and Treatment
2008 - Springer Nature | Leukemia
Laurène Fenwarth, Xavier Thomas, Stéphane de Botton, Nicolas Duployez, Jean Bourhis, Auriane Lesieur, Gael Fortin, Paul-Arthur Meslin, Ibrahim Yakoub‐Agha, Pierre Sujobert, Pierre‐Yves Dumas, Christian Récher, Delphine Lebon, Céline Berthon, Mauricette Michallet, Arnaud Pigneux, Stéphanie Nguyen, Sylvain Chantepie, Norbert Vey, Emmanuel Raffoux, Karine Celli‐Lebras, Claude Gardin, Juliette Lambert, J.‐V. Malfuson, Denis Caillot, Sébastien Maury, Benoît Ducourneau, Pascal Turlure, Émilie Lemasle, Cécile Pautas, Sylvie Chevret, Christine Terré, Nicolas Boissel, Gérard Socié, Hervé Dombret, Claude Preudhomme, Raphaël Itzykson,
Abstract A multistage model instructed by a large dataset (knowledge bank [KB] algorithm) has recently been developed to improve outcome predictions and tailor therapeutic decisions, including hematopoietic stem cell transplantation (HSCT) in acute myeloid leukemia (AML). We assessed the performance of the KB in guiding HSCT decisions in first complete remission (CR1) in 656 AML patients younger than 60 years from the ALFA-0702 trial (NCT00932412). KB predictions of overall survival (OS) were superior ...
Tópico(s): Multiple Myeloma Research and Treatments
2020 - Elsevier BV | Blood
Thomas Prébet, Steven D. Gore, Benjamin Esterni, Claude Gardin, Raphaël Itzykson, Sylvain Thépot, François Dreyfus, Odile Beyne Rauzy, Christian Récher, Lionel Adès, Bruno Quesnel, C.L. Beach, Pierre Fenaux, Norbert Vey,
Azacitidine (AZA) is the current standard of care for high-risk (ie, International Prognostic Scoring System high or intermediate 2) myelodysplastic syndrome (MDS), but most patients will experience primary or secondary treatment failure. The outcome of these patients has not yet been described.Overall, 435 patients with high-risk MDS and former refractory anemia with excess blasts in transformation (RAEB-T) were evaluated for outcome after AZA failure. The cohort of patients included four data sets ( ...
Tópico(s): Hematopoietic Stem Cell Transplantation
2011 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Raphaël Itzykson, Olivier Kosmider, Aline Renneville, Margot Morabito, Claude Preudhomme, Céline Berthon, Lionel Adès, Pierre Fenaux, Uwe Platzbecker, Olivier Gagey, Philippe Rameau, Guillaume Meurice, Cédric Oréar, François Delhommeau, Olivier Bernard, Michaëla Fontenay, William Vainchenker, Nathalie Droin, Éric Solary,
Key Points Early clonal dominance may distinguish chronic myelomonocytic leukemia from other chronic myeloid neoplasms with similar gene mutations. Early dominance of TET2-mutated cells in the hematopoietic tissue promotes myeloid differentiation skewing toward the granulomonocytic line.
Tópico(s): Myeloproliferative Neoplasms: Diagnosis and Treatment
2013 - Elsevier BV | Blood
Mireille Bousquet‐Mélou, Dave Loeb, Jean-Bernard Zuber,
Tópico(s): Algebraic and Geometric Analysis
1997 - Pergamon Press | Mathematical and Computer Modelling
Standard System Price ListKeltran Optical F = 1.0 $
Tópico(s): Historical and Literary Studies
1996 - AIP Publishing | Physics Today
Christophe Willekens, Aline Renneville, Sophie Broutin, Véronique Saada, Jean‐Baptiste Micol, J Delahousse, Vianney Poinsignon, Claire Bories, Céline Berthon, Raphaël Itzykson, Nicolas Boissel, Cyril Quivoron, Marie Terroir-Cassou-Mounat, Jacques Bosq, Claude Preudhomme, Angélo Paci, Virginie Penard‐Lacronique, Stéphane de Botton,
Tópico(s): Hematological disorders and diagnostics
2018 - Springer Nature | Leukemia
Auriane Lesieur, Xavier Thomas, Olivier Nibourel, Nicolas Boissel, Laurène Fenwarth, Stéphane de Botton, Élise Fournier, Karine Celli‐Lebras, Emmanuel Raffoux, Christian Récher, Juliette Lambert, Céline Berthon, Arnaud Pigneux, Raphaël Itzykson, Pascal Turlure, Cécile Pautas, Jacques Vargaftig, Claude Preudhomme, Hervé Dombret, Nicolas Duployez,
Not available.
Tópico(s): Acute Lymphoblastic Leukemia research
2020 - Ferrata Storti Foundation | Haematologica
Raphaël Itzykson, Sylvain Thépot, Bruno Quesnel, François Dreyfus, Christian Récher, Eric Wattel, Claude Gardin, Lionel Adès, Pierre Fenaux,
To the editor: We previously reported that peripheral blasts, performance status (PS), red blood cell (RBC) transfusion requirement, and International Prognostic Scoring System (IPSS) cytogenetic risk independently predicted inferior overall survival (OS) in 282 consecutive IPSS high- and
Tópico(s): Chronic Myeloid Leukemia Treatments
2012 - Elsevier BV | Blood
Lin‐Pierre Zhao, Bérénice Schell, Marie Sébert, Rathana Kim, Pierre Lemaire, Maxime Boy, Stéphanie Mathis, Lise Larcher, Clémentine Chauvel, Mohamed Bedis Dhouaieb, Valéria Bisio, Claude Preudhomme, Alice Marceau‐Renaut, Raphaël Itzykson, A. Mékinian, O. Fain, Antoine Toubert, Pierre Fenaux, Nicolas Dulphy, Emmanuelle Clappier, Lionel Adès,
Tópico(s): Histiocytic Disorders and Treatments
2021 - Springer Nature | Leukemia
Marie-Magdelaine Coudé, Thorsten Braun, Jeannig Berrou, Mélanie Dupont, Sibyl Bertrand, Aline Massé, Emmanuel Raffoux, Raphaël Itzykson, Marc Delord, María E. Riveiro, Patrice Herait, André Baruchel, Hervé Dombret, Claude Gardin,
The bromodomain (BRD) and extraterminal (BET) proteins including BRD2, BRD3 and BRD4 have been identified as key targets for leukemia maintenance. A novel oral inhibitor of BRD2/3/4, the thienotriazolodiazepine compound OTX015, suitable for human use, is available. Here we report its biological effects in AML and ALL cell lines and leukemic samples. Exposure to OTX015 lead to cell growth inhibition, cell cycle arrest and apoptosis at submicromolar concentrations in acute leukemia cell lines and patient- ...
Tópico(s): Ubiquitin and proteasome pathways
2015 - Impact Journals LLC | Oncotarget
Mathieu Meunier, Claude‐Eric Bulabois, Anne Thiebaut‐Bertrand, Raphaël Itzykson, Martin Carré, Sylvain Carras, Frédéric Garban, J Cahn,
Acute graft-versus-host disease (aGVHD) still remains the main cause of morbidity and mortality after allogeneic stem cell transplantation. Moreover, patients who did not respond to first-line treatment with glucocorticosteroids have a very poor outcome. Some studies suggested that alemtuzumab (a humanized monoclonal antibody against the CD52 antigen) might be effective for treatment of refractory aGVHD. Here we report a single-center experience with alemtuzumab in refractory gastrointestinal aGVHD. ...
Tópico(s): Immunotherapy and Immune Responses
2014 - Elsevier BV | Biology of Blood and Marrow Transplantation
Claude Gardin, Cécile Pautas, Élise Fournier, Raphaël Itzykson, Émilie Lemasle, Jean-Henri Bourhis, Lionel Adès, Jean-Pierre Marolleau, Jean‐Valère Malfuson, Lauris Gastaud, Emmanuel Raffoux, Juliette Lambert, Thorsten Braun, Xavier Thomas, Sylvain Chantepie, Thomas Cluzeau, Stéphane de Botton, Céline Berthon, Nicolas Boissel, Nicolas Duployez, Christine Terré, Régis Peffault de Latour, Mauricette Michallet, Karine Celli‐Lebras, Claude Preudhomme, Hervé Dombret,
Abstract In this study, we aimed to refine prognostication of older with acute myeloid leukemia (AML) after intensive chemotherapy. Five hundred and nine patients aged 60 years or older (median age, 68 years) were prospectively enrolled in the intensive Acute Leukemia French Association (ALFA)-1200 trial between 2012 and 2016, and 471 patient samples were submitted to multigene analysis. Mutations in any of 8 genes frequently altered in myelodysplastic syndromes (MDS), including ASXL1, SRSF2, STAG2, ...
Tópico(s): Acute Lymphoblastic Leukemia research
2020 - Elsevier BV | Blood Advances
Raphaël Itzykson, Claude Preudhomme,
Les syndromes myélodysplasiques (SMD) forment un ensemble hétérogène d’hémopathies myéloïdes clonales associées à un risque important de transformation en leucémie aiguë myéloïde. Les anomalies moléculaires récurrentes dans les SMD sont mal caractérisées. Elles sont pour la plupart des marqueurs de progression vers la leucémie aiguë myéloïde. Récemment, les résultats cliniques favorables d’agents thérapeutiques inhibant la préservation de la méthylation de l’ADN lors de la division cellulaire, ont ...
Tópico(s): Nuclear Structure and Function
2009 - Elsevier BV | Revue Francophone des Laboratoires
Lin‐Pierre Zhao, Maxime Boy, Célia Azoulay, Emmanuelle Clappier, Marie Sébert, Ludivine Amable, Jihène Klibi, Kamel Benlagha, Marion Espéli, Karl Balabanian, Claude Preudhomme, Alice Marceau‐Renaut, Lina Benajiba, Raphaël Itzykson, A. Mékinian, O. Fain, Antoine Toubert, Pierre Fenaux, Nicolas Dulphy, Lionel Adès,
Tópico(s): Lymphoma Diagnosis and Treatment
2021 - Springer Nature | Leukemia
Frédérik Damm, Raphaël Itzykson, Olivier Kosmider, Nathalie Droin, Aline Renneville, Virginie Chesnais, Véronique Gelsi‐Boyer, Stéphane de Botton, Norbert Vey, Claude Preudhomme, Aline Clavert, Éric Delabesse, Sophie Park, Daniel Birnbaum, Michaëla Fontenay, Olivier Bernard, Éric Solary,
Tópico(s): Vascular Tumors and Angiosarcomas
2013 - Springer Nature | Leukemia
Matthieu Duchmann, Orianne Wagner‐Ballon, Thomas Boyer, Meyling Cheok, Élise Fournier, Estelle Guérin, Laurène Fenwarth, Bouchra Badaoui, Nicolas Freynet, Emmanuel Benayoun, Daniel Lusina, Isabel García, Claude Gardin, Pierre Fenaux, Cécile Pautas, Bruno Quesnel, Pascal Turlure, Christine Terré, Xavier Thomas, Juliette Lambert, Aline Renneville, Claude Preudhomme, Hervé Dombret, Raphaël Itzykson, Thomas Cluzeau,
Tópico(s): Hematopoietic Stem Cell Transplantation
2021 - Springer Nature | Leukemia
Augustin Boudry, Sasha Darmon, Nicolas Duployez, Martin Figeac, Sandrine Geffroy, Maxime Bucci, Karine Celli‐Lebras, Matthieu Duchmann, Romane Joudinaud, Laurène Fenwarth, Olivier Nibourel, Laure Goursaud, Raphaël Itzykson, Hervé Dombret, Mathilde Hunault, Claude Preudhomme, Mikaël Salson,
Internal tandem duplications in the FLT3 gene, termed FLT3-ITDs, are useful molecular markers in acute myeloid leukemia (AML) for patient risk stratification and follow-up. FLT3-ITDs are increasingly screened through high-throughput sequencing (HTS) raising the need for robust and efficient algorithms. We developed a new algorithm, which performs no alignment and uses little resources, to identify and quantify FLT3-ITDs in HTS data.Our algorithm (FiLT3r) focuses on the k-mers from reads covering FLT3 ...
Tópico(s): Cancer Genomics and Diagnostics
2022 - BioMed Central | BMC Bioinformatics
Fernando Ramos, Sylvain Thépot, Lisa Pleyer, Luca Maurillo, Raphaël Itzykson, Joan Bargay, Reinhard Stauder, Adriano Venditti, Valérie Seegers, V. Martínez‐Robles, Sonja Burgstaller, Christian Récher, Guillermo Debén, Gianluca Gaïdano, Claude Gardin, Pellegrino Musto, Richard Greil, Fermín Sánchez‐Guijo, Pierre Fenaux,
Hypomethylating agents are able to prolong the overall survival of some patients diagnosed with acute myeloid leukemia. The aim of this study was to evaluate the clinical use of azacitidine as front-line therapy in unfit acute myeloid leukemia (AML) patients and to develop a clinical prediction model to identify which patients may benefit more from the drug. One hundred and ten untreated unfit AML patients received front-line azacitidine therapy in Spain, and response and survival were evaluated ...
Tópico(s): Myeloproliferative Neoplasms: Diagnosis and Treatment
2015 - Elsevier BV | Leukemia Research
Raphaël Itzykson, Sylvain Thépot, Virginie Éclache, Bruno Quesnel, François Dreyfus, Odile Beyne‐Rauzy, Pascal Turlure, Norbert Vey, Christian Récher, Simone Boehrer, Claude Gardin, Lionel Adès, Pierre Fenaux,
Tópico(s): Myeloproliferative Neoplasms: Diagnosis and Treatment
2011 - Springer Nature | Leukemia
... Methods, Conformal Field Theory and Random Systems. By Claude Itzykson and Jean-Michel Drouffe. Volume 1 (Cambridge University ...
Tópico(s): Theoretical and Computational Physics
1990 - Taylor & Francis | Contemporary Physics